SBIR/STTR Came Back After a Six-Month Lapse, but the Rules Changed. The New $30M Strategic Breakthrough Award and FY 2027 Proposal Caps Will Restructure How Small Businesses Compete.

For six months, no federal agency could issue a new SBIR or STTR award. The authorization expired September 30, 2025, and the legislative path to renewal stalled in committee through the fall and into early 2026. Phase I proposals already in review continued to be evaluated, but no obligations could be made against the new fiscal year's appropriation. Small businesses with strong Phase I or Phase II rankings sat in queue, agency program officers triaged the backlog, and the prime contractor ecosystem that depends on SBIR-funded small-business technology absorbed the gap. The Department of Defense's Small Business Innovation Research portfolio, which represents the largest single share of the federal SBIR/STTR program, ran on momentum from prior-year obligations.

That ended on April 13, 2026, when President Trump signed S. 3971, the Small Business Innovation and Economic Security Act. The reauthorization extends both programs through September 30, 2031 — a five-year horizon that replaces the recurring two- and three-year reauthorization cycles that have characterized SBIR/STTR for the last decade. Within two weeks of signing, the Department of War (the renamed Department of Defense) released more than 90 new topics across its components. The civilian agencies — NIH, NSF, DOE, NASA, USDA — are working through compressed FY 2026 schedules to obligate the unspent appropriation before fiscal year-end on September 30, 2026.

The headline is that the programs are back. The substantive story is that they came back materially changed. The reauthorization adds a new high-dollar award category, dramatically expands national security screening, imposes per-company proposal limits starting in FY 2027, and overhauls the Phase II-to-Phase III transition mechanics. Small businesses that built their participation model around the pre-lapse program structure — high-volume Phase I submissions, deliberate cultivation of multiple parallel Phase II awards, long Phase II to Phase III transition timelines — are now operating inside a different statute.

The Strategic Breakthrough Award

The single most consequential addition is the Strategic Breakthrough Award category. Under prior law, the SBIR program's award structure topped out at the standard Phase II ceiling — $2 million guideline at most agencies, with discretionary increases possible up to roughly $9 million under specific authorities. The new Strategic Breakthrough Awards permit up to $30 million per award with a 48-month period of performance. The mechanism is restricted: only agencies with annual extramural SBIR expenditures exceeding $100 million can offer them, and a participating agency can allocate no more than 0.5 percent of its overall extramural research and development budget to Strategic Breakthrough Awards in any year. In practice, this puts the Department of Defense, NIH, NASA, DOE, and possibly NSF in the eligible agency pool.

The eligibility constraints on small-business applicants are equally specific. Companies must demonstrate prior Phase I or Phase II experience — these are not first-time entry awards. Companies must secure matching funds equal to 100 percent of the Strategic Breakthrough Award amount from new private capital sources or non-SBIR government funding. For a $30 million award, that means $30 million in committed parallel investment. Companies must provide market research substantiating technology viability, and agencies must execute awards within 90 days of proposal receipt.

The structural logic is that Strategic Breakthrough Awards address a long-running critique of SBIR/STTR — the "valley of death" between Phase II completion and Phase III commercialization, where promising technologies stall because the next funding round requires the kind of capital that small businesses typically cannot raise without revenue traction the SBIR program does not produce. By coupling a $30 million federal award to a $30 million private matching requirement and a 90-day execution timeline, the Strategic Breakthrough mechanism is designed to bridge that valley for technologies where the agency has high confidence in the underlying capability and the small-business team. The 100 percent matching requirement also limits the pool of eligible companies to those with credible investor or strategic-partner relationships — venture-backed defense-tech firms, late-stage biotech companies with strategic-partner term sheets, and similar.

For small businesses currently holding Phase II awards in agencies with extramural SBIR budgets over $100 million, the Strategic Breakthrough Award is the new top of the funding ladder. Phase II awardees should now be modeling the matching-fund path — committed VC term sheets, strategic-partner agreements, customer co-investment commitments — alongside their Phase III commercialization planning. Companies that have historically run Phase II through to commercial sales without raising outside capital will find the Strategic Breakthrough mechanism inaccessible unless they change their capital strategy.

Foreign Affiliation Screening Across Eight Watchlists

The national security and foreign affiliation provisions in S. 3971 are the most expansive in the program's 43-year history. Agencies must now examine cybersecurity practices, patent ownership, employee composition, financial relationships, and foreign affiliations against eight federal watchlists before making any SBIR or STTR award. The watchlists include the 1260H Chinese Military Companies List, the Uyghur Forced Labor Prevention Act Entity List, the Section 889 Prohibition List, and five additional designated lists covering foreign ownership, control, or influence concerns.

The screening reach extends beyond the applicant company itself. Agencies will examine foreign affiliations of key personnel, investment relationships with individuals or entities in countries of concern, technology licensing or joint venture arrangements with foreign parties, and any business relationship that connects the applicant to flagged foreign entities. Applicants denied on national security grounds must receive notification, which is a procedural change from the prior practice of unexplained non-selections. Entities appearing on any of the eight watchlists are excluded from program participation entirely.

The operational implications for small businesses are immediate. Any company with foreign equity holders, foreign-trained technical personnel with continuing institutional affiliations abroad, licensing arrangements with foreign-domiciled entities, or supply-chain dependencies on companies based in countries of concern needs to audit its corporate structure, capitalization table, employment records, and contract portfolio against the watchlists before submitting any SBIR or STTR proposal. Companies that have raised capital from international funds — including funds with limited-partner exposure to flagged jurisdictions — should expect detailed disclosure obligations and longer pre-award review timelines. The new screening regime adds time and documentation burden to every proposal, and it will produce non-selections that prior-law non-selections would not have produced.

For companies that pass the screening cleanly, the new regime is a competitive advantage. The number of companies that can pass clean is smaller than the prior applicant pool, which means competitive density at the topic level is reduced — particularly for companies in dual-use technology areas where foreign capital and foreign technical talent have historically been common.

Proposal Caps Coming in FY 2027

Beginning in fiscal year 2027 — which starts October 1, 2026 — every federal agency participating in SBIR or STTR must set its own proposal cap limiting the number of proposals a single company can submit per fiscal year, per solicitation, or per topic. The cap design is delegated to individual agencies, so the implementation will vary: NIH may choose a per-solicitation cap, DOD components may choose per-topic caps, NSF may choose a per-fiscal-year cap. Agencies may grant waivers but only for up to 5 percent of program topics annually, which means waivers will be reserved for high-priority topics where the agency has identified a specific need.

The legislative motivation is the "SBIR Mill" problem — a small number of companies that have built their business models around very high-volume SBIR submissions, sometimes hundreds of proposals per fiscal year, with success rates that produce a steady revenue stream from Phase I awards but limited Phase III commercialization. The proposal cap mechanism does not eliminate these companies, but it forces them to concentrate their submission strategy on topics where they have the strongest technical fit and the clearest commercialization path.

For small businesses that have historically operated below the cap thresholds — companies submitting five to twenty proposals per year against carefully selected topics — the FY 2027 caps will have limited direct impact. The indirect impact is that competitive density on the most attractive topics will decrease as high-volume submitters are forced to deprioritize. For companies that have operated at high volume, the FY 2027 caps are existential. Submission strategy now needs to shift from quantity to selection quality, from broad topic coverage to deep agency relationships, and from Phase I dependence to Phase II and Phase III throughput.

The cap design also interacts with the Strategic Breakthrough Award eligibility requirements. Companies that submitted high volumes of Phase I proposals to build a portfolio for portfolio's sake will have fewer Phase II awards in the pipeline once caps take effect, which reduces the pool of companies eligible for Strategic Breakthrough Awards in subsequent years. The legislation is, in effect, channeling SBIR participation toward companies with deep agency engagement and credible commercialization paths rather than toward companies optimizing for award volume.

Phase III Transition Mechanics

The Phase II-to-Phase III transition has been the program's structural weakness for two decades. Phase III is the commercialization stage — federal procurement of the developed technology, often through sole-source contracts authorized under SBIR Phase III authority — and the legislative intent has always been that Phase II graduates would convert into Phase III contracts at meaningful rates. In practice, conversion rates have been low. Contracting officers without SBIR-specific training have defaulted to competitive procurement vehicles, primes have absorbed small-business technology through subcontract relationships rather than direct Phase III awards, and small businesses have struggled to navigate the acquisition workforce.

S. 3971 attempts to address this with three specific mechanisms. The SBA, in coordination with the Department of War and the General Services Administration, must establish training programs for contracting officers and acquisition workforce personnel on Phase III award mechanics. Federal agencies must develop simplified and standardized procedures and model contracts for Phase I, Phase II, and Phase III awards. The Department of War has also established a new Accelerated Research for Transition (ART) program within its Office for Small Business Innovation, providing additional non-dilutive capital and multiple pathways to move Phase II capabilities through production and sustainment phases.

The combined effect is that the contracting-officer side of the Phase III problem now has explicit statutory remediation, and the small-business side has a new mechanism — ART — that sits between Phase II completion and full Phase III procurement. For small businesses with Phase II awards expected to complete in FY 2026 or FY 2027, the ART program and the new standardized Phase III procedures are concrete enough to begin building transition plans against. Companies should be initiating Phase III conversations with their agency program officers and contracting officers now, before Phase II completion, rather than treating Phase III as a separate post-completion process.

The Technical and Business Assistance (TABA) program has also been expanded: Phase I awardees can now access up to $6,500 in TABA funding, and Phase II awardees up to $50,000. The TABA increase is small in dollar terms but materially useful for commercialization planning, market research, regulatory pathway analysis, and the kind of business-development support that does not fit naturally inside the technical scope of an SBIR project.

What Happens to FY 2026 Funds Not Obligated by September 30

The six-month lapse means agencies entered the second half of FY 2026 with substantial unobligated SBIR/STTR funds and compressed timelines to commit them. S. 3971 includes a carryover provision: agencies with unspent SBIR or STTR funds at the end of FY 2026 are permitted to carry those funds into FY 2027, rather than returning them to the Treasury. The provision is a recognition that the lapse-induced backlog cannot realistically be cleared in the truncated obligation window, and it prevents the lapse from translating into reduced effective program funding in FY 2027.

For small businesses, the carryover provision changes the competitive dynamics of late-FY 2026 and early FY 2027 solicitations. Agencies will have more capital available to obligate in the first half of FY 2027 than the appropriated FY 2027 amount alone would suggest. Solicitations released in the October-March window of FY 2027 are likely to fund more awards than typical years, particularly at agencies that ran the largest unobligated balances during the lapse — DOD, NIH, NSF, and DOE.

The Strategic Reframe

The combined effect of these provisions is that SBIR and STTR have shifted from a volume-friendly program structure to a selectivity-driven structure. The legislative direction of travel is consistent: fewer per-company proposals, higher-quality applicants, deeper agency relationships, stronger commercialization paths, cleaner foreign affiliation profiles, and explicit support for the small-business firms that can bridge the Phase II-to-Phase III valley with private capital. This is the program structure that the small-business defense-industrial-base advocates have been pushing for since the original SBIR Mill critiques in the 2010s. It is also the program structure that imposes the highest adjustment costs on the companies that built their participation model around the prior regime.

For companies new to SBIR/STTR — first-time Phase I applicants, university spinouts entering the program, founders evaluating SBIR as a non-dilutive funding source — the post-S. 3971 program is substantially more navigable than the pre-lapse program. Competitive density is lower, agency program officers have more capacity to engage with high-quality applicants, and the Phase II-to-Phase III transition mechanics are starting to function as designed. For companies operating at high volumes under the prior regime, the next 18 months are the window to restructure submission strategy before the FY 2027 caps take effect.

For grantseekers evaluating where SBIR/STTR fits in the broader federal small-business funding landscape, the answer after S. 3971 is that the program is more durable (five-year authorization), more selective (proposal caps, foreign affiliation screening), and more capable of funding genuine commercialization (Strategic Breakthrough Awards, ART, standardized Phase III procedures). The tradeoff is that participation now requires more deliberate strategic planning per proposal and more substantial corporate-level compliance work per submission.

Tools like Granted can map a company's technical capabilities against agency-specific topic structures, surface the Strategic Breakthrough eligibility threshold against existing Phase II portfolios, and flag the foreign affiliation disclosures that the new screening regime will require — before the proposal goes into agency review.